KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme.

María Chaparro, Remo Panaccione, Bruce E Sands, Peter M Irving, Martina Goetsch, Eugenia Kunina, Wenjin Wang, Joseph Wu, John C Woolcott, Lauren Bartolome, Christina Cognata, Karolina Wosik, Marla C Dubinsky

BMJ Open Gastroenterol 12(1) e001838

PMID40889900
PMCIDPMC12406896
DOI10.1136/bmjgast-2025-001838
发表日期2025-09-01
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 multi panel km;Figure 2:AI 判定为 multi panel km;Figure 3:AI 判定为 other。
摘要

摘要

OBJECTIVE: Bothersome ulcerative colitis (UC) symptoms include stool frequency (SF), rectal bleeding (RB), abdominal pain and bowel urgency; symptomatic relief is a key treatment goal. Etrasimod is an oral, once-daily (QD), selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately to severely active UC. We assessed outcomes related to symptomatic relief among patients with moderately to severely active UC in the phase III ELEVATE UC clinical programme. METHODS: In both ELEVATE UC 52 and ELEVATE UC 12, adults were randomly assigned (2:1) to etrasimod 2 mg QD or placebo. Symptomatic remission, symptomatic response, complete symptomatic remission, SF and RB were evaluated at each trial visit. Bowel urgency and abdominal pain were also assessed (weeks 12 and 52). RESULTS: Significantly more patients receiving etrasimod were in symptomatic remission and symptomatic response at weeks 12 and 52 versus placebo (all p<0.001). Improvements from baseline in RB and SF subscores were significantly greater in those receiving etrasimod versus placebo from weeks 2 (ELEVATE UC 12) and 4 (ELEVATE UC 52). Similarly, a significantly greater number of patients in the etrasimod versus placebo group were in complete symptomatic remission. At weeks 12 and 52, the number of patients achieving clinically meaningful improvements in bowel urgency, bowel urgency remission and abdominal pain remission was significantly greater for etrasimod versus placebo (all p<0.05). CONCLUSION: Etrasimod was efficacious in improving symptoms of UC from week 2; improvements were maintained through week 52. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov: NCT03945188; NCT03996369.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Proportions of patients achieving ( A ) symptomatic remission at each study visit, ( B ) symptomatic remission at week 52 for patients achieving symptomatic remission at week 12, ( C ) symptomatic response and ( D ) complete symptomatic remission at each study visit (MMS 4–9). Panels A, C and D include data from ELEVATE UC 52 and ELEVATE UC 12; panel B includes data from ELEVATE UC 52 only. Patients missing an assessment at the specified analysis visit were considered non-responders. *p<0.05. Δ, adjusted difference (%); MMS, modified Mayo score; QD, once daily; UC, ulcerative colitis.
非 KM Figure
Figure 2Figure 2. Proportion of patients achieving ( A ) symptomatic response over time without corticosteroid use at baseline, ( B ) symptomatic response over time with corticosteroid use at baseline, ( C ) symptomatic remission over time without corticosteroid use at baseline and ( D ) symptomatic remission over time with corticosteroid use at baseline (MMS 4–9). † Adjusted difference (%) was for etrasimod minus placebo and based on estimated common proportion difference using the Cochran-Mantel-Haenszel weighted method, stratified by naïvety to prior bio/JAKi therapy at trial entry (yes vs no) and baseline disease activity (MMS 4–6 vs 7–9). The two-sided p value tested the null hypothesis of the proportion difference being 0. Patients missing an assessment at the specified analysis visit were considered non-responders. *p<0.05. bio/JAKi, biologic/Janus kinase inhibitor; MMS, modified Mayo score; QD, once daily; UC, ulcerative colitis.
非 KM Figure
Figure 3Figure 3. The proportion of patients achieving ( A ) bowel urgency remission (NRS ≤1), ( B ) bowel urgency complete remission (NRS=0), ( C ) clinically meaningful improvement in bowel urgency (NRS ≥3-point decrease from baseline) and ( D ) abdominal pain remission (NRS=0) in ELEVATE UC 52 and ELEVATE UC 12 (MMS 4–9). For bowel urgency remission, bowel urgency complete remission and clinically meaningful improvement in bowel urgency endpoints, only patients with baseline bowel urgency NRS ≥3 were included. Δ, adjusted difference (%); MMS, modified Mayo score; NRS, numerical rating scale; QD, once daily; UC, ulcerative colitis.
非 KM Figure